The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic role that the subsidiary now plays in producing and distributing the company’s lifesaving biotherapies both inside and outside of Hungary.
Can you please provide some insight into the company’s presence within Hungary, and also describe how far the business has grown since Kedrion acquired HUMAN BioPlazma in 2008?
Kedrion has strived to ... create a unique value proposition by building productive partnerships, particularly with governments, to respond to the needs of the healthcare system and support strategic goals in plasma-derived therapies for the treatment of rare and debilitating diseases.
